Data as of Dec 04
| +0.01 / +0.21%|
The 18 analysts offering 12-month price forecasts for ARIAD Pharmaceuticals Inc have a median target of 2.50, with a high estimate of 34.00 and a low estimate of 2.00. The median estimate represents a -48.35% decrease from the last price of 4.84.
The current consensus among 22 polled investment analysts is to Hold stock in ARIAD Pharmaceuticals Inc. This rating has held steady since November, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.